Shenzhen New Industries Biomedical Engineering Co., Ltd.
Research Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) on Bullrun: market cap CNY 46.00B, P/E 25.5, dividend yield 2.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker300832.SZ
- ExchangeSZ
- CountryChina
- SectorHealthcare
- IndustryMedical Devices
- CurrencyCNY
- Market capCNY 46.00B
- P/E25.5
- Dividend yield2.1%
- Financial periodQ2 2026
- RevenueCNY 1.29B
- Net incomeCNY 425.72M
- Free cash flowCNY 449.91M
- Gross margin68.6%
Valuation Snapshot
latest market cap is CNY 46.00B; P/E is 25.5; dividend yield is 2.1%.
Peer valuation comparison
Latest P/E is 25.46x versus a Healthcare sector median of 21.8x (16.8% above).
Latest dividend yield is 2.05% versus a Healthcare sector median of 2.4% (14.6% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | CNY 46.00B | 25.5 | 2.0% | 1.2 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.2 CNY, yield 2.1%.
About Shenzhen New Industries Biomedical Engineering Co., Ltd.
Shenzhen New Industries Biomedical Engineering Co., Ltd., engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in China and internationally. It offers immunoassay analyzers, biochemistry/electrolyte, integrated system, lab automation, molecular diagnostics, hemolumi and rapid test solutions. The company was founded in 1995 and is based in Shenzhen, China.
ETFs that hold Shenzhen New Industries Biomedical Engineering Co., Ltd.
US-listed ETFs
Shenzhen New Industries Biomedical Engineering Co., Ltd. is held by 33 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares MSCI Emerging Markets ETF (EEM) | <0.01% | 0.72% |
| iShares Core MSCI Emerging Markets ETF (IEMG) | <0.01% | 0.09% |
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) | <0.01% | 0.04% |
| Xtrackers Harvest CSI 300 China A-Shares ETF (ASHR) | 0.07% | 0.65% |
| Schwab Emerging Markets Equity ETF (SCHE) | <0.01% | 0.06% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Shenzhen New Industries Biomedical Engineering Co., Ltd.'s market cap?
Shenzhen New Industries Biomedical Engineering Co., Ltd.'s market capitalization is CNY 46.00B.
What is Shenzhen New Industries Biomedical Engineering Co., Ltd.'s P/E ratio?
Shenzhen New Industries Biomedical Engineering Co., Ltd.'s price-to-earnings (P/E) ratio is 25.5.
Does Shenzhen New Industries Biomedical Engineering Co., Ltd. pay a dividend?
Shenzhen New Industries Biomedical Engineering Co., Ltd. has a dividend yield of 2.1%.
What does Shenzhen New Industries Biomedical Engineering Co., Ltd. do?
Shenzhen New Industries Biomedical Engineering Co., Ltd., engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in China and internationally. It offers immunoassay analyzers, biochemistry/electrolyte, integrated system, lab automation, molecular diagnostics, hemolumi and rapid test solutions. The company was founded in 1995 and is based in Shenzhen, China.